




Chief Scientific Officer

AC Immune
Lausanne, Switzerland



MADIHA

DEROUAZI

Biotech Entrepreneur/
Immunotherapy

Education & Training

DOCTOR OF PHILOSOPHY

2001-2005
Biotechnology
EPFL - Switzerland

POSTDOCTORAL RESEARCH FELLOW

2001-2002
Bacterial vector engineering, Cancer vaccine, Tumor associated antigens screening
CNRS, Paris - France

MAITRE ASSISTANTE

2009-2014
HUG - Genève, Switzerland

CEO

2012 - 2022
Amal Therapeutics - Geneva - CH

CEO

2021 - 2023
Speransa Therapeutics
Frankfurt - Germany

CSO

2024 - Present
AC Immune
Lausanne - Switzerland

Profile

Dr. Madiha Derouazi holds a PhD in Cellular Biotechnology from EPFL. In 2012, she founded AMAL Therapeutics, an immuno-oncology company developing next-generation cancer vaccines, where she served as both CEO and CSO. Under her leadership, AMAL was acquired by Boehringer Ingelheim. Dr. Derouazi then became CEO of Speransa Therapeutics, where she oversaw the development of a novel platform for prophylactic vaccines. She now serves as Chief Scientific Officer (CSO) at AC Immune.

Articles

Novel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats.

Press

"When you're an entrepreneur, you need to do things your way"



[linkedin.com/in/madiha-derouazi](https://www.linkedin.com/in/madiha-derouazi)



madiha.derouazi@acimmune.com